It is estimated that one in four people will require brain treatment at some point. While there are drug candidates for most diseases of the brain, the blood-brain barrier (BBB) poses an impassable obstacle for most of these compounds and a bottleneck for the delivery of drugs that could cure these patients.
In the Peptides and Proteins Lab at the Institute for Research in Biomedicine (IRB Barcelona), Dr. Meritxell Teixidó headsa line of research that, after 10 years, has led to the development of a technology called Gate2Brain. This patented technology consists of three families of peptide shuttles that have the capacity to cross the BBB, carrying with them therapeutic cargos that cannot cross this barrier alone.
This innovation project at IRB Barcelona has been awarded almost 100.000euros by the Agency for Management of University and Research Grants (AGAUR) and the Secretaria d’Univesitats i Recerca del Departament d’Empresa i Coneixement of the Catalan Government, through the 2018 “Knowledge Industry” call, which is cofunded by the 2014-2020 ERDF (European Regional Development Fund) for Catalonia.
The funding will be used to advance the proof of concept of the Gate2Brain technology for the treatment of rare paediatric brain tumours.
The Knowledge Industry Programme seeks to boost the creation and consolidation of a new business ecosystem with high added value based on research from centres devoted to knowledge generation. This programme forms part of the Research and Innovation Strategy for the Smart Specialisation of Catalonia (RIS3CAT), which promotes R+D+I as a driver of change in the productive sector.
More information: Knowledge Industry Programme